FDA Adds Warnings to Kybella Over Off-Label Use and Persistent Nodules

FDA Warns on Off-Label Kybella Injections After 129 Complication Cases

Regulators updated the labeling for Kybella, known generically as deoxycholic acid, following a comprehensive review of adverse event reports and medical literature. According to medicaltoxic.com, the agency identified 129 cases of complications stemming from injections administered outside of the approved submental region, which is the area under the chin. The updated safety communication warns patients and providers against off-label cosmetic injections across other parts of the body where safety and efficacy remain unestablished.

Severe Anatomical Risks and Cytolytic Drug Action

Administering deoxycholic acid outside of the submental fat layer introduces severe anatomical risks because the medication acts as a cytolytic drug that physically disrupts cell membranes and causes cell lysis, according to medicaltoxic.com. When practitioners place the compound in unapproved areas, patients face significant risks of nerve injury, muscle damage, and visual complications.

According to findings cited by medicaltoxic.com, the 129 off-label adverse event reports included visual disturbances resulting from periorbital use. Other reported complications involved muscle and nerve injuries such as facial paresis, paresthesia, involuntary eye contractions, weakness, numbness, and difficulty walking. Existing prescribing information already warns against marginal mandibular nerve injury, facial muscle weakness, dysphagia, tissue damage, vascular injury, injection-site ulceration, necrosis, infection, and injection-site alopecia.

Persistent Nodules and Masses Lasting Nearly Five Months

In addition to off-label hazards, the updated FDA safety communication highlights 117 cases of unresolved injection-site nodules or masses, as reported by medicaltoxic.com. Unlike the localized off-label data, these persistent tissue masses have been documented following deoxycholic acid injections in both approved and unapproved anatomical locations.

According to medicaltoxic.com, these lesions persisted for a mean duration of approximately 143 days—about five months—at the time they were formally reported to the agency. Many of these nodules and masses remained unresolved after initial or subsequent treatments, and some could require medical intervention. The FDA emphasizes that healthcare providers and patients must recognize that these tissue reactions can linger for months regardless of proper injection technique in the submental region.

Strict Labeling Adherence Urged to Prevent Permanent Damage

Kybella has maintained U.S. Food and Drug Administration approval since 2015 specifically to improve the appearance of moderate-to-severe fullness associated with submental fat in adults. The drug is not approved for treatment of subcutaneous fat elsewhere in the body.

Medical toxicologists and regulators emphasize that safety concerns stem directly from the drug’s potent pharmacology rather than cosmetic medicine in general. Because deoxycholic acid lyses fat cells, incorrect placement near vulnerable anatomical structures—including salivary glands, lymph nodes, arteries, veins, nerves, and muscles—can cause injury. Regulators urge clinicians to adhere strictly to approved labeling and proper submental injection techniques to minimize patient exposure to these severe risks.